{"id":43163,"date":"2025-10-13T17:04:44","date_gmt":"2025-10-13T09:04:44","guid":{"rendered":"https:\/\/flcube.com\/?p=43163"},"modified":"2025-10-13T17:04:44","modified_gmt":"2025-10-13T09:04:44","slug":"sichuan-biokins-systimmune-receives-250-million-triggered-by-phase-2-3-milestone-in-egfrxher3-adc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43163","title":{"rendered":"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC"},"content":{"rendered":"\n<p>China\u2011based <strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that its wholly\u2011owned subsidiary <strong>SystImmune, Inc.<\/strong> has achieved a pivotal milestone in the global <strong>Phase\u202f2\/3 IZABRIGHT\u2011Breast01<\/strong> trial of the bispecific antibody\u2011drug conjugate (ADC) <strong>iza\u2011bren (BL\u2011B01D1)<\/strong>. The achievement unlocks the first near\u2011term contingent payment of <strong>USD\u202f250\u202fmillion<\/strong> under the exclusive license and collaboration agreement with <strong>Bristol\u2011Myers Squibb Company (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>)<\/strong>, with the payment expected in the near future.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>License &amp; Collaboration<\/strong><\/td><td>Dec\u202f2023 agreement between <strong>SystImmune, Inc.<\/strong> (Sichuan Biokin) and <strong>BMS<\/strong><\/td><\/tr><tr><td><strong>Territorial Scope<\/strong><\/td><td>\u2022 <em>SystImmune<\/em> \u2013 exclusive development, commercialization, and production of BL\u2011B01D1 in mainland China; partial supply for global use.<br>\u2022 <em>BMS<\/em> \u2013 exclusive global development and commercialization outside China.<\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>\u2022 USD\u202f800\u202fmillion non\u2011refundable upfront payment (already received).<br>\u2022 Up to USD\u202f250\u202fmillion near\u2011term contingent payments (triggered by current milestone).<br>\u2022 Potential additional payments up to USD\u202f7.1\u202fbillion upon future development, regulatory, and sales milestones.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Profile<\/strong> \u2013 <strong>iza\u2011bren (BL\u2011B01D1)<\/strong> is an <strong>EGFR\u00d7HER3 bispecific ADC<\/strong> targeting HER3\u2011positive breast cancers.<\/li>\n\n\n\n<li><strong>Trial Success<\/strong> \u2013 The IZABRIGHT\u2011Breast01 study has reached a pivotal endpoint in its Phase\u202f2\/3 program, validating the clinical advantage of the bispecific ADC in HER3\u2011driven tumors.<\/li>\n\n\n\n<li><strong>Implication for Oncology<\/strong> \u2013 The milestone underscores the therapeutic potential of bispecific ADCs and positions SystImmune\/Biokin as a key partner in BMS\u2019s global oncology pipeline.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Cash Flow<\/strong> \u2013 The USD\u202f250\u202fmillion payment strengthens SystImmune\u2019s balance sheet and supports ongoing R&amp;D activities in China.<\/li>\n\n\n\n<li><strong>Revenue Upside<\/strong> \u2013 With the potential for up to USD\u202f7.1\u202fbillion in milestone payments, the agreement offers a scalable revenue engine tied to clinical success and market penetration.<\/li>\n\n\n\n<li><strong>Investor Confidence<\/strong> \u2013 The partnership exemplifies a successful public\u2011private collaboration, enhancing Biokin\u2019s reputation within the biopharmaceutical ecosystem.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h3>\n\n\n\n<p>Sichuan Biokin and BMS continue to collaborate on the development, commercialization, and production of BL\u2011B01D1 worldwide. The partnership leverages Biokin\u2019s manufacturing capabilities in China and BMS\u2019s global commercialization expertise, positioning both companies to capitalize on the growing demand for next\u2011generation ADC therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/688506_20251013_1V2U.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20251013_1V2U.\"><\/object><a id=\"wp-block-file--media-8157840d-e01c-46af-84ee-9408ac9220ec\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/688506_20251013_1V2U.pdf\">688506_20251013_1V2U<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/688506_20251013_1V2U.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8157840d-e01c-46af-84ee-9408ac9220ec\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly\u2011owned subsidiary SystImmune, Inc&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":43165,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,151,429,428,849,857],"class_list":["post-43163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-biokin-pharmaceutical","tag-bms","tag-bristol-myers-squibb","tag-nyse-bmy","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly\u2011owned subsidiary SystImmune, Inc. has achieved a pivotal milestone in the global Phase\u202f2\/3 IZABRIGHT\u2011Breast01 trial of the bispecific antibody\u2011drug conjugate (ADC) iza\u2011bren (BL\u2011B01D1). The achievement unlocks the first near\u2011term contingent payment of USD\u202f250\u202fmillion under the exclusive license and collaboration agreement with Bristol\u2011Myers Squibb Company (BMS, NYSE: BMY), with the payment expected in the near future.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43163\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly\u2011owned subsidiary SystImmune, Inc. has achieved a pivotal milestone in the global Phase\u202f2\/3 IZABRIGHT\u2011Breast01 trial of the bispecific antibody\u2011drug conjugate (ADC) iza\u2011bren (BL\u2011B01D1). The achievement unlocks the first near\u2011term contingent payment of USD\u202f250\u202fmillion under the exclusive license and collaboration agreement with Bristol\u2011Myers Squibb Company (BMS, NYSE: BMY), with the payment expected in the near future.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43163\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T09:04:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1304.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\\\/3 Milestone in EGFR\u00d7HER3 ADC\",\"datePublished\":\"2025-10-13T09:04:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163\"},\"wordCount\":366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1304.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"BMS\",\"Bristol-Myers Squibb\",\"NYSE: BMY\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43163#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43163\",\"name\":\"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\\\/3 Milestone in EGFR\u00d7HER3 ADC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1304.webp\",\"datePublished\":\"2025-10-13T09:04:44+00:00\",\"description\":\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly\u2011owned subsidiary SystImmune, Inc. has achieved a pivotal milestone in the global Phase\u202f2\\\/3 IZABRIGHT\u2011Breast01 trial of the bispecific antibody\u2011drug conjugate (ADC) iza\u2011bren (BL\u2011B01D1). The achievement unlocks the first near\u2011term contingent payment of USD\u202f250\u202fmillion under the exclusive license and collaboration agreement with Bristol\u2011Myers Squibb Company (BMS, NYSE: BMY), with the payment expected in the near future.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43163\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1304.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1304.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\\\/3 Milestone in EGFR\u00d7HER3 ADC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43163#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\\\/3 Milestone in EGFR\u00d7HER3 ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly\u2011owned subsidiary SystImmune, Inc. has achieved a pivotal milestone in the global Phase\u202f2\/3 IZABRIGHT\u2011Breast01 trial of the bispecific antibody\u2011drug conjugate (ADC) iza\u2011bren (BL\u2011B01D1). The achievement unlocks the first near\u2011term contingent payment of USD\u202f250\u202fmillion under the exclusive license and collaboration agreement with Bristol\u2011Myers Squibb Company (BMS, NYSE: BMY), with the payment expected in the near future.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43163","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC","og_description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly\u2011owned subsidiary SystImmune, Inc. has achieved a pivotal milestone in the global Phase\u202f2\/3 IZABRIGHT\u2011Breast01 trial of the bispecific antibody\u2011drug conjugate (ADC) iza\u2011bren (BL\u2011B01D1). The achievement unlocks the first near\u2011term contingent payment of USD\u202f250\u202fmillion under the exclusive license and collaboration agreement with Bristol\u2011Myers Squibb Company (BMS, NYSE: BMY), with the payment expected in the near future.","og_url":"https:\/\/flcube.com\/?p=43163","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-13T09:04:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1304.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43163#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43163"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC","datePublished":"2025-10-13T09:04:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43163"},"wordCount":366,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43163#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1304.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","BMS","Bristol-Myers Squibb","NYSE: BMY","SHA: 688506"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43163#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43163","url":"https:\/\/flcube.com\/?p=43163","name":"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43163#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43163#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1304.webp","datePublished":"2025-10-13T09:04:44+00:00","description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly\u2011owned subsidiary SystImmune, Inc. has achieved a pivotal milestone in the global Phase\u202f2\/3 IZABRIGHT\u2011Breast01 trial of the bispecific antibody\u2011drug conjugate (ADC) iza\u2011bren (BL\u2011B01D1). The achievement unlocks the first near\u2011term contingent payment of USD\u202f250\u202fmillion under the exclusive license and collaboration agreement with Bristol\u2011Myers Squibb Company (BMS, NYSE: BMY), with the payment expected in the near future.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43163#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43163"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43163#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1304.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1304.webp","width":1080,"height":608,"caption":"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43163#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin\u2019s SystImmune Receives $250\u202fMillion Triggered by Phase\u202f2\/3 Milestone in EGFR\u00d7HER3 ADC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1304.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43163"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43163\/revisions"}],"predecessor-version":[{"id":43166,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43163\/revisions\/43166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43165"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}